gadodiamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diagnostic agents, gadolinium derivatives	4494	131410-48-5

Description:

Molecule	Description
Synonyms: omniscan gadodiamide	for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions Molecular weight: 573.66 Formula: C16H26GdN5O8 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

omniscan
gadodiamide

for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions

Molecular weight: 573.66
Formula: C16H26GdN5O8
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.79 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.46 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 8, 1993	FDA	GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	2221.55	55.36	349	2613	4116	56284989
Skin hypertrophy	407.91	55.36	79	2883	3131	56285974
Skin induration	406.54	55.36	78	2884	2940	56286165
Skin tightness	309.29	55.36	65	2897	3890	56285215
Fibrosis	198.22	55.36	45	2917	3846	56285259
Skin fibrosis	197.87	55.36	35	2927	829	56288276
Skin hyperpigmentation	153.51	55.36	39	2923	5358	56283747
Joint range of motion decreased	136.55	55.36	51	2911	25314	56263791
Joint contracture	110.37	55.36	24	2938	1678	56287427
Scar	105.14	55.36	35	2927	12398	56276707
Emotional distress	94.70	55.36	41	2921	29722	56259383
Skin discolouration	92.20	55.36	42	2920	34314	56254791
Anhedonia	80.20	55.36	27	2935	9887	56279218
Peau d'orange	76.28	55.36	12	2950	134	56288971
Joint stiffness	72.65	55.36	36	2926	35389	56253716
Oedema peripheral	70.99	55.36	64	2898	171190	56117915
Erythema	70.05	55.36	61	2901	155878	56133227
Mobility decreased	68.63	55.36	50	2912	98941	56190164
Skin plaque	64.24	55.36	21	2941	7017	56282088
Muscle contracture	61.21	55.36	14	2948	1230	56287875
Extremity contracture	60.83	55.36	14	2948	1265	56287840
Deformity	60.19	55.36	22	2940	10233	56278872
Pain	59.37	55.36	116	2846	663068	55626037
Magnetic resonance imaging head abnormal	55.87	55.36	14	2948	1812	56287293

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	2296.10	53.98	386	2782	3569	31690607
Skin hypertrophy	378.09	53.98	79	3089	2386	31691790
Skin tightness	357.19	53.98	73	3095	1971	31692205
Skin induration	356.55	53.98	73	3095	1989	31692187
Joint range of motion decreased	238.71	53.98	66	3102	6595	31687581
Joint contracture	237.51	53.98	51	3117	1752	31692424
Skin fibrosis	217.60	53.98	43	3125	970	31693206
Fibrosis	180.49	53.98	43	3125	2366	31691810
Scar	167.19	53.98	48	3120	5482	31688694
Extremity contracture	132.97	53.98	27	3141	700	31693476
Deformity	128.61	53.98	30	3138	1503	31692673
Emotional distress	125.80	53.98	49	3119	14307	31679869
Mobility decreased	122.16	53.98	58	3110	27411	31666765
Joint stiffness	112.45	53.98	41	3127	9980	31684196
Anhedonia	104.60	53.98	36	3132	7406	31686770
Pain	85.87	53.98	99	3069	186660	31507516
Oedema peripheral	84.66	53.98	77	3091	109762	31584414
Injury	82.64	53.98	40	3128	19669	31674507
Skin disorder	70.47	53.98	31	3137	12250	31681926
Skin discolouration	68.05	53.98	33	3135	16274	31677902
Skin hyperpigmentation	64.56	53.98	20	3148	2951	31691225
Musculoskeletal stiffness	64.48	53.98	44	3124	41281	31652895

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	3114.19	52.88	503	4194	5549	70918198
Skin hypertrophy	615.65	52.88	123	4574	4529	70919218
Skin induration	589.03	52.88	117	4580	4178	70919569
Skin tightness	528.30	52.88	110	4587	4980	70918767
Skin fibrosis	319.68	52.88	59	4638	1406	70922341
Joint range of motion decreased	276.52	52.88	92	4605	25934	70897813
Joint contracture	268.62	52.88	55	4642	2277	70921470
Fibrosis	243.54	52.88	58	4639	4836	70918911
Scar	195.78	52.88	61	4636	13920	70909827
Biopsy brain abnormal	174.34	52.88	21	4676	8	70923739
Skin hyperpigmentation	172.72	52.88	47	4650	6668	70917079
Joint stiffness	140.88	52.88	61	4636	35115	70888632
Oedema peripheral	136.68	52.88	116	4581	227975	70695772
Emotional distress	131.21	52.88	59	4638	37129	70886618
Skin discolouration	131.00	52.88	59	4638	37266	70886481
Mobility decreased	124.36	52.88	80	4617	102919	70820828
Anhedonia	122.47	52.88	43	4654	14170	70909577
Extremity contracture	116.30	52.88	26	4671	1634	70922113
Deformity	115.25	52.88	36	4661	8261	70915486
Peau d'orange	103.86	52.88	18	4679	295	70923452
Skin disorder	100.21	52.88	46	4651	30311	70893436
Pain	91.76	52.88	155	4542	628661	70295086
Erythema	86.98	52.88	85	4612	199478	70724269
Muscle contracture	83.64	52.88	21	4676	2173	70921574
Skin plaque	81.97	52.88	29	4668	9754	70913993
Injury	72.10	52.88	48	4649	65197	70858550
Musculoskeletal stiffness	68.19	52.88	65	4632	147695	70776052
Magnetic resonance imaging head abnormal	66.66	52.88	18	4679	2474	70921273
Pruritus	63.67	52.88	95	4602	345465	70578282
Muscle tightness	62.56	52.88	25	4672	11737	70912010
Skin exfoliation	61.63	52.88	39	4658	48587	70875160
Anxiety	59.49	52.88	73	4624	220257	70703490
Pain of skin	58.73	52.88	23	4674	10243	70913504
Muscular weakness	58.46	52.88	58	4639	138278	70785469
Magnetic resonance imaging abnormal	57.78	52.88	17	4680	3183	70920564
Gait disturbance	57.68	52.88	66	4631	185040	70738707
Dry skin	54.30	52.88	38	4659	55893	70867854

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08CA03	VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Paramagnetic contrast media
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals
FDA MoA	N0000175862	Magnetic Resonance Contrast Activity
FDA EPC	N0000180184	Paramagnetic Contrast Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Magnetic resonance imaging	indication	113091000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D04284	KEGG_DRUG
4020689	VUID
N0000148302	NUI
4020689	VANDF
CHEBI:31642	CHEBI
CHEMBL1200346	ChEMBL_ID
C064925	MESH_SUPPLEMENTAL_RECORD_UI
6636	INN_ID
DB00225	DRUGBANK_ID
84F6U3J2R6	UNII
41144	RXNORM
10205	MMSL
4771	MMSL
d04083	MMSL
004259	NDDF
354088005	SNOMEDCT_US
396067007	SNOMEDCT_US
C0082646	UMLSCUI
153921	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0691	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections